ATE352638T1 - REVERSE ßTWO-HYBRIDß-SYSTEME - Google Patents

REVERSE ßTWO-HYBRIDß-SYSTEME

Info

Publication number
ATE352638T1
ATE352638T1 AT96912683T AT96912683T ATE352638T1 AT E352638 T1 ATE352638 T1 AT E352638T1 AT 96912683 T AT96912683 T AT 96912683T AT 96912683 T AT96912683 T AT 96912683T AT E352638 T1 ATE352638 T1 AT E352638T1
Authority
AT
Austria
Prior art keywords
protein
methods
rna
reverse
hybrid systems
Prior art date
Application number
AT96912683T
Other languages
English (en)
Inventor
Marc Vidal
Jef D Boeke
Ed Harlow
Original Assignee
Gen Hospital Corp
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Univ Johns Hopkins filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE352638T1 publication Critical patent/ATE352638T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/37—Assays involving biological materials from specific organisms or of a specific nature from fungi
    • G01N2333/39—Assays involving biological materials from specific organisms or of a specific nature from fungi from yeasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Direct Current Motors (AREA)
  • Bridges Or Land Bridges (AREA)
  • Dram (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Paper (AREA)
AT96912683T 1995-04-11 1996-04-11 REVERSE ßTWO-HYBRIDß-SYSTEME ATE352638T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42052595A 1995-04-11 1995-04-11

Publications (1)

Publication Number Publication Date
ATE352638T1 true ATE352638T1 (de) 2007-02-15

Family

ID=23666820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912683T ATE352638T1 (de) 1995-04-11 1996-04-11 REVERSE ßTWO-HYBRIDß-SYSTEME

Country Status (9)

Country Link
US (7) US5955280A (de)
EP (1) EP0830459B1 (de)
JP (2) JPH11502717A (de)
AT (1) ATE352638T1 (de)
AU (1) AU716893B2 (de)
CA (1) CA2217545A1 (de)
DE (1) DE69636866D1 (de)
NZ (2) NZ502795A (de)
WO (1) WO1996032503A1 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE352638T1 (de) * 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
US5830751A (en) * 1996-05-01 1998-11-03 The Johns Hopkins University Genetic assays and strains using human TP53
US6083693A (en) 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
US6897017B1 (en) * 1997-01-31 2005-05-24 Odyssey Thera Inc. Vivo library-versus-library selection of optimized protein-protein interactions
CA2205888A1 (en) 1997-07-11 1999-01-11 John J. Priatel Complementation trap
US5885779A (en) * 1997-09-09 1999-03-23 University Of British Columbia Repressed trans-activator system for characterization of protein-protein interactions
PL340433A1 (en) * 1997-11-10 2001-02-12 Gen Hospital Corp Detection systems for detecting and recording protein-specific actions and functional interactions
US6905818B1 (en) 1997-11-27 2005-06-14 Max-Planck-Gesellschaft Zur Forderungder Wissenschaften Method for the identification and characterization of interacting molecules by automated interaction mating
CA2311896A1 (en) * 1997-11-27 1999-06-24 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Improved method for the identification and characterization of interacting molecules using automation
WO1999035282A1 (en) * 1998-01-09 1999-07-15 Tvw Telethon Institute For Child Health Research Peptide detection method
WO2000018964A1 (en) 1998-09-30 2000-04-06 Boston Medical Center Corporation Identification of virulence determinant activators in prokaryotic pathogens
US6063578A (en) * 1998-10-22 2000-05-16 Signal Pharmaceuticals, Inc. Dual reporter system and methods of use therefor
US6203986B1 (en) * 1998-10-22 2001-03-20 Robert H. Singer Visualization of RNA in living cells
EP1171595A1 (de) 1999-04-12 2002-01-16 Agensys, Inc. 13-transmembrane protein welches in prostatakrebs exprimiert wird
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
EP1173560A1 (de) 1999-04-30 2002-01-23 Hybrigenics S.A. Ansammlung von prokaryotischen dna für two-hybrid systeme helicobacter pylori protein-protein-wechselwirkungen und verwendung davon
ATE420175T1 (de) 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
JP4272376B2 (ja) 1999-10-05 2009-06-03 アジェンシス，インコーポレイテッド 前立腺ガンにおいてアップレギュレートされるｇタンパク質結合レセプターおよびその使用
US6790607B1 (en) * 1999-10-07 2004-09-14 Hybrigen, Inc. Adjustable sensitivity, genetic molecular interaction systems, including protein-protein interaction systems for detection and analysis
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
DE19957065B4 (de) 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
EP1268842B1 (de) * 2000-03-08 2006-06-21 Phylogica Limited Verbessertes verfahren für reverses n-hybrid-screening
US20030211495A1 (en) * 2000-03-08 2003-11-13 Richard Hopkins Reverse n-hybrid screening method
AU2001245584B2 (en) * 2000-03-08 2007-02-08 Phylogica Limited Improved reverse n-hybrid screening method
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US7029847B2 (en) 2000-05-16 2006-04-18 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
US6902882B2 (en) 2000-05-23 2005-06-07 Kerong Gu Methods of monitoring production of gene products and uses thereof
US6406863B1 (en) * 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
JP2004511219A (ja) 2000-07-12 2004-04-15 アジェンシス，インコーポレイテッド 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
US6787321B1 (en) 2000-10-13 2004-09-07 The Regents Of The University Of California Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products
AU2002225623A8 (en) * 2000-11-17 2009-07-30 John G Wise Creation and identification of proteins having new dna binding specificities
CA2439263C (en) * 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US20030170722A1 (en) * 2001-03-02 2003-09-11 Mcfadden Grant Methods and reagents for regulating apoptosis
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
EP2280030A3 (de) 2001-04-10 2011-06-15 Agensys, Inc. Nukleinsäuren und zugehörige Proteine für die Behandlung und den Nachweis von Krebs
US6841352B2 (en) 2001-06-29 2005-01-11 Myriad Genetics, Inc. Mating-based method for detecting protein—protein interaction
AU2002367839A1 (en) * 2001-07-16 2003-11-17 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
US6833441B2 (en) * 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
EP2287186B1 (de) 2001-09-06 2014-12-31 Agensys, Inc. Nucleinsäure und entsprechendes Protein, STEAP-1, bei der Behandlung und zum Nachweis von Krebs
US7175983B2 (en) * 2001-11-02 2007-02-13 Abmaxis, Inc. Adapter-directed display systems
WO2003040401A2 (en) * 2001-11-07 2003-05-15 Curagen Corporation General screening method for ligand-protein interactions
US20040161753A1 (en) * 2001-11-16 2004-08-19 Wise John G. Creation and identification of proteins having new dna binding specificities
AU2003224674A1 (en) * 2002-03-11 2003-09-29 Hk Pharmaceuticals, Inc. Compounds and methods for analyzing the proteome
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
SG153699A1 (en) * 2003-01-16 2009-07-29 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
CA2860151A1 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
JP2006525817A (ja) * 2003-05-09 2006-11-16 ヘルス　リサーチ　インコーポレイテッド タンパク質の相互作用の決定のための改良法
CA2526274C (en) 2003-05-30 2015-12-01 Agensys, Inc. Prostate stem cell antigen (psca) variants and subsequences thereof
US20060286600A1 (en) * 2003-06-30 2006-12-21 Albertha Walhout High throughput one-hybrid system
ATE469984T1 (de) 2003-12-01 2010-06-15 Life Technologies Corp Rekombinationsstellen enthaltende nukleinsäuremoleküle und verfahren zur verwendung davon
EP1729793B1 (de) 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 und myostatin-hemmer zur behandlung von muskelschwund
EP1753871B1 (de) 2004-05-28 2015-07-15 Agensys, Inc. An psca-proteine bindende antikörper und verwandte moleküle
US8034553B2 (en) 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
ES2561048T3 (es) 2004-07-23 2016-02-24 Acceleron Pharma Inc. Polipéptidos del receptor ActRII
FR2877010B1 (fr) * 2004-10-25 2007-03-16 Aventis Pharma Sa Systeme double-hybride base sur la mise sous silence de genes par interference transcriptionnelle
EP3300739A3 (de) 2005-03-31 2018-07-18 Agensys, Inc. An 161p2f10b-proteine bindende antikörper und zugehörige moleküle
ME00380B (me) 2005-11-23 2011-10-10 Acceleron Pharma Inc Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti
CN104524548A (zh) 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US9526759B2 (en) 2007-02-01 2016-12-27 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201940502A (zh) 2007-02-02 2019-10-16 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
KR101672156B1 (ko) 2007-02-09 2016-11-02 악셀레론 파마 인코포레이티드 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도
US7932030B2 (en) * 2007-04-05 2011-04-26 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College System for pulling out regulatory elements using yeast
JP5933894B2 (ja) 2007-09-14 2016-06-15 アディマブ， エルエルシー 合理的に設計された、合成抗体ライブラリおよびその使用
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN107412734A (zh) 2007-09-18 2017-12-01 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
CN107252486B (zh) 2008-06-26 2021-10-22 阿塞勒隆制药公司 激活素-actrii的拮抗剂及在提高红细胞水平中的用途
LT3750552T (lt) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf gaudyklės
US20100075326A1 (en) * 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
JP5755635B2 (ja) 2009-03-30 2015-07-29 アクセルロン ファーマ， インコーポレイテッド Ｂｍｐ−ａｌｋ３アンタゴニストおよび骨成長促進のためのその使用
MX385318B (es) 2009-06-08 2025-03-18 Acceleron Pharma Inc Metodos para aumentar adipocitos termogenicos.
CA2770822C (en) 2009-08-13 2020-03-24 Acceleron Pharma Inc. Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
ES2613523T3 (es) 2009-09-09 2017-05-24 Acceleron Pharma, Inc. Antagonistas de ActRIIb y dosificación y usos de los mismos
US20110129469A1 (en) 2009-11-03 2011-06-02 Acceleron Pharma Inc. Methods for treating fatty liver disease
EP2501400B1 (de) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib-proteine und varianten davon sowie ihre anwendung zur utrophin-induktion für therapien gegen muskuläre dystrophie
US20130035255A1 (en) 2010-03-26 2013-02-07 Integratech Proteomics, Llc Controlled release hybrid systems
KR102810907B1 (ko) 2010-07-16 2025-05-21 아디맵 엘엘씨 항체 라이브러리
US20140378537A1 (en) 2011-09-09 2014-12-25 Genentech, Inc. Treatment of th17 mediated inflammatory diseases
EP3520805B1 (de) 2011-10-17 2021-03-10 Acceleron Pharma Inc. Zusammensetzungen zur behandlung von myelofibrose
US8903454B2 (en) * 2011-11-07 2014-12-02 Alcatel Lucent Base station and radio unit for creating overlaid sectors with carrier aggregation
RU2018145985A (ru) 2012-11-02 2019-02-18 Селджин Корпорейшн Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
CN105658672A (zh) 2013-08-22 2016-06-08 阿塞勒隆制药公司 TGF-β受体II型变体及其用途
MX388380B (es) 2014-04-18 2025-03-19 Acceleron Pharma Inc Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
DK3227675T3 (da) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
HK1250373A1 (zh) 2015-04-06 2018-12-14 Acceleron Pharma Inc. Alk7:actriib异多聚体和其用途
MD3280727T2 (ro) 2015-04-06 2021-06-30 Acceleron Pharma Inc Proteine de fuziune ale receptorului de tip I și de tip II cu un singur braț și utilizările acestora
US11013781B2 (en) 2015-07-01 2021-05-25 Alk-Abelló As Peptide combinations and uses thereof for treating grass allergy
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
EP3370754A4 (de) 2015-11-04 2019-10-23 Acceleron Pharma Inc. Verfahren zur erhöhung der erythrozytenkonzentration und behandlung von ineffizienter erythropoiese
CA3005975A1 (en) 2015-11-23 2017-06-01 Acceleron Pharma Inc. Methods for treating eye disorders
US20170306027A1 (en) 2016-04-06 2017-10-26 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
ES2646388B1 (es) * 2016-05-11 2018-10-15 Consejo Superior De Investigaciones Científicas (Csic) Método de doble híbrido en reverso para la identificación de mutaciones missense
BR112018074472A2 (pt) 2016-05-27 2019-03-19 Synthex, Inc. interfaces proteicas
RU2748278C2 (ru) 2016-07-15 2021-05-21 Акселерон Фарма Инк. Композиции и способы лечения легочной гипертензии
EA201990226A1 (ru) 2016-07-27 2019-08-30 Акселерон Фарма Инк. Способы и композиции для лечения миелофиброза
CN109996817A (zh) 2016-09-15 2019-07-09 艾科赛扬制药股份有限公司 扭转原肠胚形成多肽及其用途
JP7280182B2 (ja) 2016-10-05 2023-05-23 アクセルロン ファーマ インコーポレイテッド バリアントＡｃｔＲＩＩＢタンパク質およびその使用
US11976111B2 (en) 2016-10-05 2024-05-07 Acceleron Pharma Inc. ActRIIa and ALK4 polypeptides for treating kidney fibrosis, inflammation and injury
CN110785431B (zh) 2017-05-04 2024-05-07 阿塞勒隆制药公司 TGF-β受体II型融合蛋白及其用途
SMT202400437T1 (it) 2017-06-14 2024-11-15 Celgene Corp Metodi per trattare mielofibrosi associata a neoplasia mieloproliferativa e anemia
GB2584211B (en) * 2017-11-16 2023-05-24 Synthex Inc Selective modulation of protein-protein interactions
GB2584210B (en) 2017-11-22 2022-03-16 Synthex Inc Peptides for inhibiting RAD51
JP6920978B2 (ja) * 2017-12-18 2021-08-18 浜松ホトニクス株式会社 画像取得装置及び画像取得方法
WO2019157342A1 (en) 2018-02-09 2019-08-15 Acceleron Pharma Inc. Methods for treating heterotopic ossification
GB201802744D0 (en) * 2018-02-20 2018-04-04 Longas Tech Pty Ltd Method
JP7773376B2 (ja) 2019-05-15 2025-11-19 シンセックス， インコーポレイテッド タンパク質の選択的分解
KR102507489B1 (ko) * 2020-12-24 2023-03-08 가톨릭대학교 산학협력단 진단 분류 장치 및 방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
KR930703462A (ko) * 1990-09-24 1993-11-30 로저 브렌트 검색 분석 방법
AT395385B (de) 1990-12-13 1992-12-10 Voest Alpine Krems Tauchrohr fuer vorrichtungen zum auftrennen von stoffgemengen
US5192238A (en) * 1992-07-14 1993-03-09 Brown John B Self-activated man overboard recovery system
DE69333969T2 (de) * 1992-10-30 2006-09-14 The General Hospital Corp., Boston Wechselwirkendes Fallensystem zur Isolierung von Proteinen
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5525490A (en) * 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US6770446B1 (en) 1994-06-14 2004-08-03 Wyeth Cell systems having specific interaction of peptide binding pairs
US5989808A (en) 1994-06-14 1999-11-23 American Cyanamid Company Identification of compounds affecting specific interaction of peptide binding pairs
US5695941A (en) * 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
EP0773952B1 (de) * 1994-07-20 2003-11-12 The General Hospital Corporation Interaktions-fullensysteme zum nachweis von protein-interaktionen
EP0775206A1 (de) * 1994-07-22 1997-05-28 Novartis AG Duales hybridsystem
US5610015A (en) * 1995-03-23 1997-03-11 Wisconsin Alumni Research Foundation System to detect protein-RNA interactions
ATE352638T1 (de) 1995-04-11 2007-02-15 Gen Hospital Corp REVERSE ßTWO-HYBRIDß-SYSTEME
US5989909A (en) * 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof

Also Published As

Publication number Publication date
EP0830459B1 (de) 2007-01-24
EP0830459A4 (de) 2002-02-27
WO1996032503A1 (en) 1996-10-17
US20030068612A1 (en) 2003-04-10
US20030124538A1 (en) 2003-07-03
CA2217545A1 (en) 1996-10-17
US20060223089A1 (en) 2006-10-05
AU5541296A (en) 1996-10-30
JPH11502717A (ja) 1999-03-09
US20050053913A1 (en) 2005-03-10
NZ502795A (en) 2001-09-28
US5955280A (en) 1999-09-21
AU716893B2 (en) 2000-03-09
US7601533B2 (en) 2009-10-13
JP2007075107A (ja) 2007-03-29
DE69636866D1 (en) 2007-03-15
US20020197627A1 (en) 2002-12-26
US7033768B2 (en) 2006-04-25
EP0830459A1 (de) 1998-03-25
NZ306767A (en) 2000-03-27
US5965368A (en) 1999-10-12

Similar Documents

Publication Publication Date Title
ATE352638T1 (de) REVERSE ßTWO-HYBRIDß-SYSTEME
ATE315087T1 (de) Neuartige auf p53 ansprechende gene
AU4969996A (en) Methods for the isothermal amplification of nucleic acid molecules
ATE211174T1 (de) Thymidin-kinase-mutanten
NO973838L (no) DNA-molekyler, deres fremstilling samt anvendelse ved genterapi
RU95110871A (ru) Способы определения нуклеотидной последовательности
EP1092771A3 (de) Tetracyclin-regulierte Transcriptionsmodulatoren
ATE295429T1 (de) Two-hybrid-screeningverfahren unter verwendung des bakteriellen transcriptionsaktivators sigma- 54
CY1111006T1 (el) Εκριμματαση ασθενειας alzheimer
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DK0973928T3 (da) DNA-baseret transposonsystem til indføring af nukleinsyre i DNA i en celle
HUP9900018A1 (hu) Cirkuláris DNS-molekula feltételes replikációs origóval, eljárás előállítására és génterápiában való felhasználására
MY157028A (en) Mammalian cytokine, related reagents
ATE290077T1 (de) Regulierte gene und ihre verwendungen
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2000069896A3 (en) Molecular interactions in haematopoietic cells
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
WO2002042422A3 (en) Molecular interactions in hematopoietic cells
WO2002040668A3 (de) Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen
HUP9900750A2 (hu) Gén kifejezésére szolgáló promóterek
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
DE69739346D1 (de) Gereinigtes sr-p70 protein
WO1997024446A3 (en) Gene delivery vehicle-targeting ligands
ATE266731T1 (de) Neue menschliche proteine, die cyclin abhängigen kinasen ähneln, sowie methoden zu deren verwendung
PT1058739E (pt) Metodo para produzir perfis de expressao genica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties